Sugi Predict

Sugi Predict / Compounds / SCHEMBL847606

SCHEMBL847606

SCHEMBL847606

CON(C)C(=O)c1ccc(C)nc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 4/20 0.43
▸ RAB9A P51151 2/20 0.37
▸ PKM P14618 1/20 0.37
▸ PIK3CA P42336 2/20 0.36
▸ MTOR P42345 2/20 0.36
▸ CLK1 P49759 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ DYRK1B Q9Y463 1/20 0.35
▸ TRPM8 Q7Z2W7 1/20 0.35
▸ SLC6A3 Q01959 1/20 0.35
▸ MLYCD O95822 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ PDE4A P27815 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ PDE4C Q08493 1/20 0.34
▸ PDE4D Q08499 1/20 0.34
▸ MAPT P10636 2/20 0.33
▸ NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3700292 0.85 TUBB4A (0.43) RAB9APKMPIK3CAMTORCLK1
SCHEMBL29663634 0.85 TUBB4A (0.43) RAB9APKMPIK3CAMTORCLK1
SCHEMBL29845286 0.84 MEN1 (0.38) EGFRRAB9APKMPIK3CAMTOR
SCHEMBL16460198 0.83 NNMT (0.40) RAB9APIK3CAMTORCLK1DYRK1A
SCHEMBL5425587 0.83 EGFR (0.47) EGFRSMN1; SMN2ALDH1A1MAPK1KMT2A
SCHEMBL18864488 0.83 POLB (0.45) RAB9APKMPIK3CAMTORCLK1
SCHEMBL20116582 0.81 MLYCD (0.38) RAB9APKMPIK3CAMTORCLK1
SCHEMBL30851652 0.81 PIK3CA (0.37) PIK3CAMTORCLK1DYRK1ADYRK1B
SCHEMBL1325615 0.79 PDE4B (0.38) RAB9APKMPIK3CAMTORCLK1
SCHEMBL3778708 0.79 TUBB4A (0.46) RAB9APKMMLYCDPDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4532485-A1 TYK2 INHIBITORS AND USES THEREOF Sudo Biosciences Limited (GB) 2025-04-09 — — EP disclosed
CN-119751448-A Preparation method of 3-iodo-6-methyl-1H-pyrazolo [3,4-b ] pyridine 上海医药集团(本溪)北方药业有限公司 2025-04-04 — — CN disclosed
EP-4504716-A1 COMPOUNDS AND METHODS OF TREATING CANCERS Cullgen (Shanghai), Inc. (CN) 2025-02-12 — — EP disclosed
CN-119156381-A Compounds and methods for treating cancer 上海睿跃生物科技有限公司 2024-12-17 — — CN disclosed
WO-2023227946-A1 TYK2 INHIBITORS AND USES THEREOF SUDO BIOSCIENCES LIMITED (GB) 2023-11-30 — — WO disclosed
WO-2023227946-A1 TYK2 INHIBITORS AND USES THEREOF SUDO BIOSCIENCES LIMITED (GB) 2023-11-30 — — WO disclosed
CN-117120440-A TYK2 inhibitor and application thereof 苏多生物科学有限公司 2023-11-24 — — CN disclosed
WO-2023193760-A1 COMPOUNDS AND METHODS OF TREATING CANCERS CULLGEN (SHANGHAI) , INC. (CN) 2023-10-12 — — WO disclosed
US-20230295179-A1 EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO EFFECTOR THERAPEUTICS, INC. 2023-09-21 — — US disclosed
US-9957277-B2 eIF4A-inhibiting compounds and methods related thereto EFFECTOR THERAPEUTICS, INC. (US) 2018-05-01 — — US disclosed
EP-2148862-A1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. Hoffmann-Roche AG (CH) 2010-02-03 — — EP disclosed
EP-2138489-A1 NOVEL PYRIMIDINE COMPOUND HAVING BENZYL(HETEROCYCLICMETHYL)AMINE STRUCTURE AND PHARMACEUTICAL PRODUCT CONTAINING THE SAME Kowa Company. Ltd. (JP) 2009-12-30 — — EP disclosed
US-20090062306-A1 NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME KOWA COMPANY, LTD. (JP) 2009-03-05 — — US disclosed
WO-2009015917-A2 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 — — WO disclosed
WO-2009015917-A2 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. HOFFMANN-LA ROCHE AG (CH) 2009-02-05 — — WO disclosed
WO-2008138920-A1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. HOFFMANN-LA ROCHE AG (CH) 2008-11-20 — — WO disclosed
WO-2008138920-A1 DIHYDROQUINONE AND DIHYDRONAPHTHRIDINE INHIBITORS OF JNK F. HOFFMANN-LA ROCHE AG (CH) 2008-11-20 — — WO disclosed
US-20080287458-A1 Dihydroquinone and dihydronaphthridine inhibitors of JNK ROCHE PALO ALTO LLC 2008-11-20 — — US disclosed
US-20080287458-A1 Dihydroquinone and dihydronaphthridine inhibitors of JNK ROCHE PALO ALTO LLC 2008-11-20 — — US disclosed
US-20080287458-A1 Dihydroquinone and dihydronaphthridine inhibitors of JNK ROCHE PALO ALTO LLC 2008-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295179-A1 EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO EIF4A1, EIF4A2, EIF4A3 EGFR 3051/4885RAB9A 1143/4885PKM 1252/4885
US-20090062306-A1 NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME CETP, MTTP, NPC1L1 EGFR 2830/4885RAB9A 1632/4885PKM 3594/4885
US-20080287458-A1 Dihydroquinone and dihydronaphthridine inhibitors of JNK MAPK9, MAPK10, MAPK1 EGFR 163/4885RAB9A 669/4885PKM 3845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.